Akers Biosciences Announces A Leadership Change Strategic Update Legal Settlement And An Aim Update | Latest News RSS feed

Akers Biosciences Announces A Leadership Change Strategic Update Legal Settlement And An Aim Update - Latest News


Akers Biosciences Announces a Leadership Change, Strategic Update, Legal Settlement and an AIM Update

Howard R. Yeaton has been appointed to the position of Chief Executive Officer effective immediately. Mr. Yeaton’s role of Chief Executive Officer is not a board position although he will work very cl... read more

Akers Biosciences Announces Q2 and H1 2018 Earnings

THOROFARE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) — Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reports its ... read more

Akers Biosciences Announces Q3 2018 Earnings

THOROFARE, N.J., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (AKER ... $104,094), on account of our settlement with Pulse, and a decline in the sales of Breath Alcohol products Q3 gross ... read more

Looking for another news?


Half Yearly Report

Launched Akers Wellness product line with two new rapid breath tests ... 2015 and 2014 as well as the percentage of change year-over-year: read more


Paternoster Resources hooks investors as it unveils bid to reduce costs

Natural resource investor Paternoster Resources plc (LON:PRS) shares zipped up over 10% to 0.155p as it issued a strategic update. It reckons its corporate ... across an expanded 3.6 kilometres. Akers ... read more

Form 10-K Taxus Cardium Pharmaceut For: Dec 31

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. ¨ Yes x No Indicate by check mark if the registrant is not required to file repo... read more

3rd Quarter 2018 Results

About Akers Biosciences ... risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to public... read more

E. I. du Pont de Nemours' (DD) CEO Ellen Kullman on Q2 2014 Results - Earnings Call Transcript

We will continue to make strategic investments in research, application development and customer facing resources to drive future growth. Operating margins are expected to continue the trend of year-o... read more

Akers Shareholders: Bernstein Liebhard LLP Announces Investigation Of Akers Biosciences, Inc. - AKER

NEW YORK, June 13, 2018 /PRNewswire/ -- Bernstein Liebhard LLP is investigating potential securities fraud claims on behalf of shareholders of Akers Biosciences ... Please follow us for updates on Lin... read more

Akers Biosciences announces a leadership change and a strategic update

Akers Biosciences (NASDAQ:AKER) announces a leadership change, an update to the Company’s business strategy, the settlement of its lawsuit with Pulse Health LLC and the resignation of its Nominated Ad... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us